PL410101A1 - Krem do stosowania w diagnostyce i terapii z zastosowaniem metody fotodynamicznej - Google Patents
Krem do stosowania w diagnostyce i terapii z zastosowaniem metody fotodynamicznejInfo
- Publication number
- PL410101A1 PL410101A1 PL410101A PL41010114A PL410101A1 PL 410101 A1 PL410101 A1 PL 410101A1 PL 410101 A PL410101 A PL 410101A PL 41010114 A PL41010114 A PL 41010114A PL 410101 A1 PL410101 A1 PL 410101A1
- Authority
- PL
- Poland
- Prior art keywords
- cream
- constituting
- cream composition
- composition
- representing
- Prior art date
Links
- 239000006071 cream Substances 0.000 title abstract 11
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 230000000536 complexating effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 229950010481 5-aminolevulinic acid hydrochloride Drugs 0.000 abstract 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical group NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 abstract 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229940082500 cetostearyl alcohol Drugs 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 229940057995 liquid paraffin Drugs 0.000 abstract 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 abstract 1
- 235000019271 petrolatum Nutrition 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003871 white petrolatum Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Krem charakteryzuje się tym, że substancją czynną jest chlorowodorek kwasu 5-aminolewulinowego stanowiący od 17% do 18% składu kremu, składnikiem podłoża jest wazelina biała stanowiąca od 3% do 4% składu kremu, kolejnym składnikiem podłoża jest alkohol cetostearylowy stanowiący od 7% do 9% składu kremu, w skład podłoża wchodzą także: parafina ciekła stanowiąca od 3% do 4% składu kremu, emulgator stanowiący od 2% - 4% składu kremu, glikol propylenowy stanowiący od 10% do 11% składu kremu. Substancją kompleksującą jest O-Fenantrolina stanowiąca od 2% do 3% składu kremu, kolejną substancją kompleksującą jest cytrynian sodu stanowiący od 2% do 3% składu kremu. Rozpuszczalnikiem jest woda oczyszczona stanowiąca od 46% do 50% składu kremu.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL410101A PL229756B1 (pl) | 2014-11-12 | 2014-11-12 | Krem do stosowania w diagnostyce i terapii z zastosowaniem metody fotodynamicznej |
| PCT/PL2015/000184 WO2016076738A1 (en) | 2014-11-12 | 2015-11-12 | Cream for the use in diagnosis and therapy with the photodynamic method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL410101A PL229756B1 (pl) | 2014-11-12 | 2014-11-12 | Krem do stosowania w diagnostyce i terapii z zastosowaniem metody fotodynamicznej |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL410101A1 true PL410101A1 (pl) | 2016-05-23 |
| PL229756B1 PL229756B1 (pl) | 2018-08-31 |
Family
ID=55077613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL410101A PL229756B1 (pl) | 2014-11-12 | 2014-11-12 | Krem do stosowania w diagnostyce i terapii z zastosowaniem metody fotodynamicznej |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL229756B1 (pl) |
| WO (1) | WO2016076738A1 (pl) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK159567C (da) | 1988-03-22 | 1991-04-02 | Rasmussen Kann Ind As | Kombinationskarm med en lodret doerpart og en skraa vinduespart |
| JPH08175986A (ja) * | 1994-09-20 | 1996-07-09 | Johnson & Johnson Medical Inc | 経皮活性を示す５−アミノレブリン酸含有薬学組成物 |
| GB0700580D0 (en) | 2007-01-11 | 2007-02-21 | Photocure Asa | Use |
| US9241921B2 (en) * | 2011-05-02 | 2016-01-26 | Pankaj Modi | Photosensitizer composition for treating skin disorders |
| CN103816539B (zh) | 2014-03-18 | 2015-07-22 | 翔宇药业股份有限公司 | 一种包含盐酸氨基乙酰丙酸的药物组合物 |
-
2014
- 2014-11-12 PL PL410101A patent/PL229756B1/pl unknown
-
2015
- 2015-11-12 WO PCT/PL2015/000184 patent/WO2016076738A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL229756B1 (pl) | 2018-08-31 |
| WO2016076738A1 (en) | 2016-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018000179A (es) | Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| MX2015009602A (es) | Piridona amidas como moduladores de canales de sodio. | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EP2670397A1 (en) | Pharmaceutical formulations including an amine compound | |
| EA201690930A1 (ru) | Композиции и способы модуляции фарнезоидных х-рецепторов | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| EA201691808A1 (ru) | Кортикостероидные композиции для местного применения | |
| EA201591499A1 (ru) | Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза) | |
| EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| CL2021002149A1 (es) | Formulación de afabicin, método para elaborar la misma | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта |